Challenges in Drug Decision Making


1
Challenges in Drug Decision Making

• Julienne Kirk Pharm.D. CDE
• Associate Professor
• Department of Family and
• Community Medicine

2
1x a week 1x a month 1x a year

• 66 year old full professor at WFU comes in and
  states she received the results from her recent
  DEXA scan
• Her Z score is -2.5 at her hip
• She is post-menopausal and reports intolerance to
  weekly Fosomax
• What are her options and she wants details

3
Bisphonsphonates for Osteoporosis

• Alendronate (Fosamax) 10 mg daily 1127 or 70 mg
  weekly 1090 Fosomax Plus D 70 mg witj 2800
  units D3 1097 5600 imots 1084
• Ibandronate (Boniva) 2.5 mg daily 1077 or 150
  mg monthly 1030 or 3mg IV every 3 mo. 1911
• Risedronate (Actonel) 5mg daily (1077) 35 mg
  weekly 1076 or 75 mg x 2 days monthly 1078
  Actonel 35 mg weekly with Calcium 500 mg other
  days of the week 1074
• Reclast IV infusion

4
Zoledronic acid (Reclast)

• Indications
• Treatment of osteoporosis in postmenopausal women
• Treatment of Pagets disease of bone in men and
  women
• MOA
• Bisphosphonate
• Inhibits osteoclast-mediated bone resorption

5
(No Transcript)
6
Zoledronic acid (Reclast)

• Efficacy HORIZON Recurrent Fracture Trial
• n2100 post-surgical repair of hip fracture
• 5 mg yearly follow-up 2 years
• New fractures
• Zoledronic acid 8.6
• Placebo 13.9 (35 reduction)
• Hip
• Zoledronic acid 2.0
• Placebo 3.5 (30 reduction)

7
Zoledronic acid (Reclast)

• Efficacy HORIZON Recurrent Fracture Trial
• Vertebral
• Zoledronic acid 1.7
• Placebo 3.8 (46 reduction)
• Death
• Zoledronic acid 9.6
• Placebo 13.3

8
Zoledronic acid (Reclast)

• Adverse effects
• Infusion reaction fever flu-like symptoms
  headache arthralgia/myalgia
• Other muscle pain
• GI disturbances
• Jaw osteonecrosis (one patient high dose
  bisphophonate was used)
• Atrial fibrillation
• IV bisphosphonates have been associated with
  renal impairment
• Transient decreases in calcium

9
Zoledronic acid (Reclast)

• Dosage / Administration
• Osteoporosis
• 5 mg once yearly IV over 15 minutes
• Daily requirement of calcium 1200 mg /
• vitamin D 400-800 IU
• Pagets Disease
• 5 mg IV over 15 minutes
• Daily requirement of calcium 1500 mg
• vitamin D 800 IU esp for 2 weeks
• Not recommended in severe renal impairment
• Patient should be sufficiently hydrated

10
My Child is Coughing

• Mom comes in with her 3 year old and states that
  she can no longer buy OTC cough and cold
  medicines
• She wants to know how to get a good night sleep
  tonight
• Mom went to the pharmacy and they told her all
  infant and cold meds have been withdraw because
  of questions about efficacy and safety issues

11
Alternatives

• Saline Nasal Spray if used in kids the first
  dose loosens the mucus and reapplication will be
  necessary
• Humidifiers and vaporizers can moisten the air
  but must be cleaned often
• If parents are using camphor menthol or
  eucalyptus for cough or congestion then do not
  allow inhalation (worry about absorption and
  liver damage
• Honey may help to relieve cough

12
Allergy Dilemma

• 64 year old female with hay fever. Other meds
  include Ditropan Diazepam Tramadol
  Cyclobenzaprine Aspirin and Lisinopril.
• She states she is highly allergic to dust
• Xyzal is what her friend uses and she wants a
  prescription for this new drug
• She also want to know about nasal steroids and if
  they will have an affect on blood sugar

13
Allergy Case Dilemma

• 40 million people suffer from allergic rhinitis
• 56 have nasal allergies throughout the year
• Xyzal (levocetirizine) has a 2 fold greater
  affinity for H1 receptors than cetirizine
• Onset at 60 minutes efficacy demonstrated at 24
  hours
• Side effects include somnolence (5)
  nasopharangitis (5) dry mouth 2-3

14
Allergy Case Discussion

• Xyzal (levocetirizine) son of Zyrtec
  indicated in the relief o symptoms associated
  with allergic rhinitis (seasonal and perennial)
  and the symptoms of uncomplicated idiopathic
  urticaria in adults and children 6 years old
• Dosage 5 mg daily for 12 years pediatric
  patients 2.5 mg daily at bedtime

15
(No Transcript)
16
Allergic Rhinitis Treatment

• Mainstay oral antihistamines
• irritative symptoms
• First vs Second-generation drugs
• Oral decongestants for obstructive sx
• Topical decongestants for temporary relief
• Topical steroids
• major impact on obstructive nasal sx less on
  irritative
• most effective per guidelines
• Ipratropium useful for watery rhinorrhea

17
Dosage

• Levocetirizine (Xyzal)
• 12 yo 5 mg q PM
• 6 11 yo 2.5 mg q PM
• Fluticasone furoate (Veramyst 27.5 mcg/spray)
• 12 yo 2 sprays each nostril daily
• 2 11 yo 1 spray each nostril daily

18
(No Transcript)
19
Allergy Medicine Cost

• Cost of antihistamines
• OTC products and competition
• 4 WalMart Loratidine 10 mg 30
• Insurance coverage Xyzal 3rd copay 50
• Fexofendine 40
• Cost of intranasal steroids
• Flovent 86 Fluticasone 60
• Nasacort 88
• Rhinocort 91
• Vancenase/Beconase 118
• Veramist

20
Typical Short Visit

• 61 year old male with a PMH of HTN type 2
  diabetes gall stones gout and hyperlipidemia.
  His A1C is 8.8 and BP is 150/88 cholesterol
  profile showed a TC of 305 LDL 165 HDL 42 and
  TG 339. His height is 510 and he weighs 244
  lbs.
• What should you think about for pharmacotherapy
  treatment regimen. Current medications include
  Lipitor 10 mg daily lopressor 25 mg bid and
  metformin 1000 mg bid and Avandia 4 mg daily.
• His has CHD in his family and his daughter who is
  in medical school has several questions one is
  about Avandia and CV data

21
Cardiovascular Drug Issues

• Do you add an aspirin today
• Do you add an ACEI
• Do you leave the beta-blocker
• What you do about Avandia
• What evidence do you have to support your
  decisions in this 15 minute visit today
• Is there evidence to support monitoring his blood
  glucose daily for better A1c control
• What labs do you want and why)

22
Aspirin Guidelines

• ADA recommends all patients take a daily aspirin
  for CV protection
• Contraindications include allergy AAA severe GI
  bleed
• Document on medical history
• Blood pressure should be controlled before you
  start aspirin therapy because of the risk of
  hemorragic stroke in the face of high BP
• Have BP

23
ADA and EASD Treatment Algorithm

• Lifestyle Intervention and metformin are
  recommended for initial therapy
• Meta-analysis (Nissen et al. 2007 NEJM) found a
  30 to 40 relative increase in risk for MI
• Another meta-analysis using a similar data set
  showed no increaser risk of CV mortality (Lago et
  al. 2007 Lancet)
• RECORD (Rosiglitazone Evaluation for Cardiac
  Outcomes and Regulation of Glycemia in Diabetes
  showed no significant increase in MI

24
Avandia vs. Actos

• Label Changes No longer indicated as a diabetes
  treatment in combination with insulin however it
  is not contraindicated
• Initiation of TZD in NYHA III or IV heart failure
  is CONTRAINDICATED
• TZD can cause or exacerbate CHF evaluate
  patient of rapid weight gain dyspnea and or
  edema
• Pioglitazone (Actos) has 19 randomized studies of
  16900 patients ranging 4 months to 3.5 years.
  MI stroke or death occurred in 375 (4.4) of
  8544 patients vs. 450 (5.7) of 7836 patients
  on control theapy

25
To TZD of not to TZD

• Both TZDs have been associated with an increased
  risk for fractures particularly in women (distal
  forearm hand and wrist) or lower limb (foot
  ankle fibula and tibia)
• ADA and EASD Treatment Algorithm states that TZD
  are 2nd line and notes that they are associated
  with an increased risk of fluid retention CHF
  and fractures.
• Rosilgitazone has been associated with macular
  edema

26
B-Blocker for Hypertension

• Cochrane Review 2007 Issue 1 Wisonge et al.
• Objective of review was to evaluate the
  effectiveness and safety of B-blockers on
  morbidity and mortality endpoints in adults with
  hypertension
• 13 RCT (n91561) in comparison with thiazides
  CCB RAS inhibitors showed that B-blockers did
  not reduce stroke and had an absence of overall
  effect on CHD when compared to the other agents
• Atenolol was the primary B-blocker in these trials

27
Hypertension 4 Examples

• Atenolol 25 mg 30
• Chlorthalidone 25 mg 30
• Diltiazem 60 mg 60
• Lisinopril 10 mg 30
• Furosemide 40 mg 30
• Metoprolol 50 mg 60
• Spironolactone 25 mg 30
• Propanolol 20 mg 60

www.target.com / www.walmart.com
28
Cardiology Survival Tips Adult Dosing Guide

• Common drugs used in the adult cardiovascular
  setting including PK parameters such as age
  gender comorbidties phenotype weight and
  interacting drugs
• In general steady-state drug levels are reached
  within 3-5 half-lives
• Last up-dated 6/07

29
CAP In Patient vs. Out Patient

• 59 year old female with a PMH significant for
  COPD Afib depression and high cholesterol. Now
  6 day h/o productive cough fever with
  occasional chills. She smokes 1 PPD. Some
  weakness but no respiratory distress. - nv
  headache MS change or diarrhea. PE. - VS - RR-
  22 (unlabored) bp-120/60 p-108 temp- 101. Pulse
  ox. 91
• Medications Atrovent and Advair Inhalers Zocor
  40 mg daily Zoloft 100 mg daily and Coumadin 5
  mg daily and Amlodipine 5 mg daily
• Chest - rales at lung bases RL. No wheezing
  scattered rhonchi CXR - Patchy RLL pneumonia

30
WFUBMC Empiric Antibiotic Recommendations for
Infections with and without Sepsis

• CAP Ceftriaxone Azithromycin
• Pneumonia in LTCF Assisted Living
  Aspiration AECB and Pen Allergy alternatives
• Skin Soft Tissue and Bone Infections
• Abdominal Infection
• UTI
• Catheter Related Infection
• Fever and Neutropenia

31
IDSA Guidelines - CAP in Outpatients

• Recommended treatments for CAP in outpatients
  are
• Previously healthy
• No recent antibiotic therapy macrolide or
  doxycycline
• Recent antibiotic therapy a respiratory
  fluoroquinolone an advanced macrolide plus high
  dose amoxicillin or an advanced macrolide plus
  high dose amoxicillin-clavulanate

Adapted from Mandell LA et al. Clin Infect Dis.
2006 1405-1433
32
IDSA Guidelines - CAP in Outpatients

• Recommended treatments for CAP in outpatients
  are
• Comorbidities (COPD malignancy diabetes renal
  or CHF)
• No recent antibiotic therapy an advanced
  macrolide or respiratory fluoroquinolone
• Recent antibiotic therapy a respiratory
  quinolone alone or an advanced macrolide plus
  beta-lactam
• Suspected aspiration with infection Augmentin
  or clindamycin
• Influenza with bacterial superinfection a
  beta-lactam or respiratory fluoroquinolone

33
Respiratory Med Cost

• Cost of current medications
• Advair 250/50 185.22
• Atrovent 0.03 64.63
• Advair (Salmeterol/Fluticasone) HFA
• --45/21 165
• --115/21 170
• --230/21 229
• Symbicort 160/4.5ug - 120 dose
  -Budesonide/Formoterol
• Symbicort 80/4.5 135

Prices www.walgreens.com / www.drugstore.com
34
Cost of Antibiotics

• Cost of treatment for CAP
• No recent antibiotic therapy
• Azithromycin 500 mg daily x 7 days 151
• Clarithromycin XL 500 mg pack 234
• Doxycycline 100 mg BID x 10 days 4.00
• Recent Antibiotic therapy
• Moxifloxacin 400 mg daily for 7-14 days 327
• Amoxicillin 1 gram TID 10-14 days 16
• Augmentin XR (1000/62.5) Two 1000 mg tablets
  every 12 hours for 7-10 days 96

Prices www.walgreens.com / www.drugstore.com
35
Antibiotics 4 Examples

• Amoxicillin 500 mg 30
• Cephalexin 500 mg 30
• Ciprofloxacin 500 mg 30
• Metronidazole 500 mg 14
• Penicillin VK 250 mg 28
• SMZ/TMP DS 800/160 20
• Tetracycline 500 mg 60

www.target.com / www.walmart.com
36
Antidepressant 4 Examples

• Amitriptyline 75 mg 30
• Citalopram 40 mg 30
• Fluoxetine 10 mg 30
• Paroxetine 20 mg 30
• Trazodone 100 mg 30
• Doxepin 25 mg 30

www.target.com / www.walmart.com
37
Retapamulin ointment (Altabax)

• Indication topical treatment of impetigo
• Up to 100 cm2 (adults) or 2 total BSA (children)
• Caused by Staphylococcus aureus or Streptococcus
  pyogenes
• MOA
• interacts with 50S subunit of the bacterial
  ribosome

38
Impetigo

• Usually affects children
• Transmitted via direct contact
• Types nonbullous bullous
• Prognosis
• Guidelines
• Topical treatment for limited disease
• Oral antibiotics for more severe disease

39
Retapamulin ointment (Altabax)

• Efficacy
• 85 versus 50 placebo
• 90 for both retapamulin vs cephalexin po
• Safety
• Application site irritation (1.5)
• Drug interactions none clinically important

40
Treatment of Impetigo
41
Paliperidone (Invega)

• Indication acute and maintenance treatment of
  schizophrenia
• MOA
• 9-hydroxyrisperidone
• Central dopamine Type 2 (D2) and serotonin Type 2
  (5HT2A) receptor antagonism

42
Paliperidone (Invega)

• Pharmacokinetics
• Osmotic delivery (OROSTM)once daily interval
• Metabolism limited role of CYP2D6 3A4
• Elimination 80 urine 10 feces
• Drug interactions
• Caution with other centrally-acting drugs
• May lessen effects of levodopa / dopamine
  agonists
• Avoid drugs prolonging QT interval

43
Paliperidone (Invega)

• Adverse effects
• tachycardia headache sedation anxiety
• QT prolongation (4)
• dizziness nausea tremor
• Other class labeling with regard to
• neuroleptic malignant syndrome
• orthostatic hypotension
• tardive dyskinesia
• seizure risk
• ed mortality in elderly with dementia-related
  psychosis

44
Second Generation Antipsychotics Comparative
Adverse Effects
Limited experience likely similar to risperidone
Med Lett Drug Ther 20074921
45
Paliperidone (Invega)

• Dosage / Administration
• 6 mg daily range 3 12 mg
• 3 6 9 mg available
• No titration necessary
• Renal impairment
• CrCL 50-79 mL/min 6 mg max
• CrCL 10-49 mL/min 3 mg max
• Do not crush
• Insoluble core eliminated in stool

46
2nd Generation AntipsychoticsComparative Cost
Adapted from Med Lett Drug Ther 20074922
47
Paliperidone (Invega)

• Summary
• Major metabolite of risperidone
• Effective compared to placebo
• No current comparisons to other active drugs
• Similar adverse effects expected fewer drug
  interactions
• Fewer indications and dosage forms
• Generic risperidone to come

48
Rotigotine (Neupro)

• Indication treatment of signs/symptoms of
  early-stage idiopathic Parkinsons disease
• MOA
• Non-ergot dopamine agonist
• Matrix patch

49
Parkinsons Disease

• Cardinal features
• Tremor rigidity bradykinesia
• Postural instability
• Symptom control challenges
• Wearing-off
• On-off
• Dyskinesias

50
Parkinsons Disease

• Cardinal features
• Tremor rigidity bradykinesia
• Postural instability
• Symptom control challenges
• Wearing-off
• On-off
• Dyskinesias

51
Rotigotine (Neupro)

• Efficacy
• Early PD
• Versus placebo improvements in motor and
  daily living scores
• Versus ropinirole both drugs vs placebo
• Advanced PD (2.5 hrs off time)
• Versus placebo 1-2 hrs more improvement
• Versus pramipexole both drugs 2 hrs vs
  placebo
• Restless Legs
• Versus placebo

52
Rotigotine (Neupro)

• Availability 2- 4- 6-mg/24 hr patches
• Dosage / Administration
• Initial 2 mg / 24 hr
• Titrate in weekly intervals taper on d/c
• Apply to abdomen hip thigh flank shoulder or
  upper arm
• Rotate sites over 14-day period
• Avoid direct heat
• Contains aluminum

53
Rotigotine (Neupro)

• Adverse effects
• Application site reactions
• Nausea somnolence dizziness
• Sudden sleep onset
• Hallucinations abnormal dreaming
• Postural hypotension
• Weight gain peripheral edema
• Contains sodium metabisulfite

54
Rotigotine (Neupro)

• Summary
• Initial therapy for Parkinsons
• Levodopa vs anticholinergic vs dopamine agonist
  vs selegiline
• Once daily administration
• Similar adversities to dopaminergic agents
• Unclear benefit to continuous dopaminergic
  stimulation
• Cost